Highlights include:
• Once-weekly vs twice weekly carfilzomib for newly diagnosed MM
• Negative trials for pembrolizumab in treatment naive and relapsed/refractory MM
• Daratumumab plus dexamethasone in triple refractory MM
Download here: Multiple Myeloma Research Review Issue 32